Skip to main content Accessibility help
×
Home
Hostname: page-component-7bb4899584-w6929 Total loading time: 0.464 Render date: 2023-01-27T04:34:13.523Z Has data issue: true Feature Flags: { "useRatesEcommerce": false } hasContentIssue true

Autoimmune Inflammatory Myopathy after Treatment with Ipilimumab

Published online by Cambridge University Press:  02 December 2014

Gary Hunter*
Affiliation:
Department of Neurology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
Chris Voll
Affiliation:
Department of Neurology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
Christopher A. Robinson
Affiliation:
Department of Pathology and Laboratory Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
*
Royal University Hospital, Dept of Neurology, 103 Hospital Drive, Saskatoon, Saskatchewan, S7N 0W8, Canada
Rights & Permissions[Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Brief Communications
Copyright
Copyright © The Canadian Journal of Neurological 2009

References

1. Cranmer, LD, Hersh, E. The role of the CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest. 2007;25(7): 61331.CrossRefGoogle ScholarPubMed
2. Attia, P, Phan, GQ, Maker, AV, Robinson, MR, Quezado, MM, Yang, JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic Tlymphocyte antigen-4. J Clin Oncol. 2005;23(25):604353.CrossRefGoogle Scholar
3. Ribas, A, Camacho, LH, Lopez-Berestein, G, Pavlov, D, Bulanhagui, CA, Millham, R, et al. Antitumor activity in melanoma and antiself responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005;23(35):896877.CrossRefGoogle Scholar
4. Tchekmedyian, S, Glasby, J, Korman, A, Keler, T, Deo, Y, Davis, T. MDX-010 (human anti-CTLA-4): a phase I trial in malignant melanoma. [abstract] Proc Am Soc Clin Oncol. 2002; 2:56.Google Scholar
5. Phan, GQ, Haworth, LR, Duray, PH, Davis, TA, Rosenberg, SA. Blockade of CTLA-4 with MDX-010 in humans can induce both autoimmunity and cancer regression. [abstract] Proc Am Soc Clin Oncol. 2003; 22: 3424.Google Scholar
6. Maker, AV, Phan, GQ, Attia, P, Yang, JC, Sherry, RM, Topalian, SL, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyteassociated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005, 12(12), 100516.CrossRefGoogle Scholar
7. Weber, J. Review: Anti-CTLA-4 Antibody Ipilimumab: case studies of clinical response and immune-related adverse events. The Oncologist. 2007;12:86472.CrossRefGoogle ScholarPubMed
8. Beck, KE, Blansfield, JA, Tran, KQ, Feldman, AL, Hughes, MS, Royal, RE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte associated antigen 4. J Clin Oncol. 2006;24:22839.CrossRefGoogle ScholarPubMed
9. Colucci, F, Bergman, ML, Penha-Goncalves, C, Cilio, CM, Holmberg, D. Apoptosis resistance of nonobese diabetic peripheral lymphocytes linked to the Idd5 diabetes susceptibility region. Proc Natl Acad Sci USA. 1997;94:86704.CrossRefGoogle ScholarPubMed
10. Greve, B, Vijayakrishnan, L, Kubal, A, Sobel, RA, Peterson, LB, Wicker, LS, et al. The diabetes susceptibility locus Idd5.1 on mouse chromosome 1 regulates ICOS expression and modulates murine experimental autoimmune encephalomyelitis. J Immunol. 2004;73:15763.CrossRefGoogle Scholar
11. Ueda, H, Howson, JM, Esposito, L. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature. 2003;423:50611.CrossRefGoogle ScholarPubMed
12. Wang, HB, Shi, FD, Li, H, Chambers, BJ, Link, H, Ljunggren, HG. Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol. 2001;166 (10):64306.CrossRefGoogle ScholarPubMed
You have Access
82
Cited by

Save article to Kindle

To save this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Autoimmune Inflammatory Myopathy after Treatment with Ipilimumab
Available formats
×

Save article to Dropbox

To save this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about saving content to Dropbox.

Autoimmune Inflammatory Myopathy after Treatment with Ipilimumab
Available formats
×

Save article to Google Drive

To save this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about saving content to Google Drive.

Autoimmune Inflammatory Myopathy after Treatment with Ipilimumab
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *